Supplementation of YMETA, on Gut Health, Immunity and Metabolism in Pre-diabetic Adult Population

Launched by UNIVERSITY OF ROEHAMPTON · May 27, 2022

Keywords

ClinConnect Summary

Y META is a combination of gut health focused bioactives that target both the metabolic activity of existing microbiota (Bifidobacterium spp. targeting prebiotic galacto-oligosaccharides mixture) and the crosstalk of existing microbiota with host mucosal immune system through gut microbiota derived signalling molecules (Bifidobacterium derived polysaccharides commercially available as Y SKIN) that interact with the gut mucosal immune system to promote its regulatory activity and prevent accumulation of gut derived chronic inflammation, in order to revert insulin resistance, the main risk fa...

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Adults aged between 18 and 60 years, with
• • Fasting blood glucose level of 5.6-6.9mmol/L or
• • Impaired HbA1c (HbA1c level of 5.7%-6.4%)
• • For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.
• • Exclusion criteria
• • People with a current diagnosis or clinical history of T2DM
• • People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, uncontrolled hypertension, cancer or major psychiatric or cognitive problems
• • People who are already participating in a weight loss programme
• • People receiving drug treatment for pre-diabetes (eg, metformin)
• • People with a history of long-term use of medicines known to influence glucose metabolism (eg, corticosteroids)
• • People with elevated liver enzymes (alanine aminotransferase ≥300 IU/L, aspartate aminotransferase ≥300 IU/L)
• • People who take antibiotics or bacterial agents (Probiotics) within 1 month
• • Pregnant women, women ready for pregnancy, and nursing mothers